Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients An Observational Study Conducted Among Chinese NSCLC Patients to Evaluate Osimertinib Safety Profile in a Real World Setting

NCT03485326 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03485326
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03485326 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC Patients An Observational Study Conducted Among Chinese NSCLC Patients to Evaluate Osimertinib Safety Profile in a Real World Setting
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
April 21, 2020
Completion date
August 3, 2023
Enrollment
1,700 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer